EUCTR2006-000383-88-HU进行中（未招募）不适用
A Multicenter, Parallel-group, Double-blind, Placebo Controlled and Randomized Clinical Study to Assess the Efficacy and Safety of Ketoprofen 10% Cutaneous Spray versus Placebo in Patients with Acute Ankle Sprains (AAS)
CSC Pharmaceuticals Handels GmbH0 个研究点目标入组 240 人开始时间: 2006年3月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject diagnosed with an acute ankle sprain of external lateral ligament defined as degree I or II in the O’Donoghue classification or as stage I or II in the Castaing classification (for details see references as well as short reminder at the end of this document), and fulfilling the following criteria:
- •-Post-traumatic sprain caused by medial inversion of the ankle.
- •-Pain on active motion assessed by the patient must correspond to = 50 mm VAS at baseline.
- •-Uncomplicated ankle sprain, i.e. treatable without surgery, and including injuries not associated with concomitant problems that contraindicate early motion and rehabilitation.
- •-Onset within 48 hours prior to the first visit, medically untreated as yet except for paracetamol (last dose not later than 6h prior to the baseline visit) or other type II analgesics e.g. dextropropoxifen (last dose not later than 12h prior to the baseline visit) or ice packs (last application not later than 1 hour prior to the baseline visit).
- •·Male or female outpatients
- •·Aged 18-65 years
- •·If female of childbearing potential:
- •-agree to maintain reliable birth control (oral contraceptive, IUDs, sterilized partner) throughout the study.
- •-or with negative (urine) pregnancy test in countries where required (by the Ethic’s Committee).
- •·Subject who, in the opinion of the investigator, would understand the meaning of the information sheet, would be co-operative and sufficiently reliable to use the medication as instructed, complete the diary and return for follow-up visits.
- •·Subject has provided written informed consent prior to undergoing any study procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Criteria concerning ankle sprain:
- •·Who has a complicated ankle sprain, i.e.
- •-Requiring surgery
- •-Not meeting degree I or II or stage I or II for ankle sprain according to O’Donoghue and Castaing classification, respectively.
- •-Where radiography is indicated according to the Ottawa rules.
- •·Who has undergone another course of treatment for the ankle sprain e.g. cast or other immobilizing (i.e. inhibition of dorso-flexion) bandage or system.
- •·Who has recurrent ankle sprain (i.e. a previous episode within the last 6 months).
- •·Who has bilateral ankle sprain.
- •·Who has had a major surgery of the affected joint during the 6 months preceding inclusion.
- •Criteria concerning previous and concomitant medication and other therapy:
- •·Who has started treatment with antidepressants, muscle relaxants or tranquilizers within 1 month of enrolment, or who is likely to change the dose of such concomitant drugs during the course of the study.
- •·Who is taking or has taken any form, including topical, of opioid, NSAID (except for low dose aspirin 200mg or less that was started at least 30 days prior to enrolment, and that will not be changed during the study), or any other analgesic within 7 days of inclusion (or 15 days for oxicams).
- •·Who is unable to walk without aid or using crutches.
- •·Who has taken any other investigational drug within the past 30 days.
- •·Receiving therapy with agents known or likely to interact with study drug, see section 8 of protocol.
- •Criteria concerning the subject:
- •·Who is pregnant or breast-feeding.
- •·Who has a known hypersensitivity to ketoprofen, or who has an allergy manifested by attacks of asthma, urticaria, or acute rhinitis following treatment with aspirin or other agents with cyclo-oxygenase inhibiting activity such as non-steroidal anti-inflammatory drugs (NSAIDs).
- •·Who has a known hypersensitivity to paracetamol.
- •·Who is suffering from known liver, kidney, cardiovascular, pulmonary or hematological disease.
- •·Who is suffering from phlebitis.
- •·Who has suffered from an ulcer, gastrointestinal bleeding and/or perforation within 2 years prior to the trial.
- •·With evidence or history of drug or alcohol abuse.
- •·Who has previously participated in this clinical study.
- •·Who has skin lesions or wounds in the affected area on the ankle to be treated.
- •·With mental impairment limiting the ability to comply with study requirements.
- •·Who, in the opinion of the investigator, is unable or unwilling to complete the study.
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Parallel-group, Double-blind, Placebo Controlled and Randomized Clinical Study to Assess the Efficacy and Safety of Ketoprofen 10% Cutaneous Spray versus Placebo in Patients with Acute Ankle Sprains (AAS)Painful, acute ankle sprains, as a model of general traumatic soft-tissue injuriesMedDRA version: 8.1Level: LLTClassification code 10002549EUCTR2006-000383-88-SKCSC Pharmaceuticals Handels GmbH240
招募中
1 期
A Study of Nicotine Freshmint Mouthspray in E-cigarette Users Willing to QuitVaping cessation in e-cigarette usersMedDRA version: 21.1Level: LLTClassification code: 10056484Term: Nicotine craving Class: 10037175CTIS2023-505036-35-00McNeil AB800
进行中（未招募）
不适用
A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C, at the doses of 2, 8 and 20 mg/d for 4 weeks, using donepezil as calibrator, in patients with mild Alzheimer's Disease - NDMedDRA version: 9.1Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)Alzheimer's DiseaseEUCTR2007-001639-80-ITsanofi-aventis recherche & de'veloppement200
进行中（未招募）
1 期
A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C, at the doses of 2, 8 and 20 mg/d for 4 weeks, using donepezil as calibrator, in patients with mild Alzheimer's Disease.Alzheimer's DiseaseEUCTR2007-001639-80-FRsanofi-aventis recherche & développement200
进行中（未招募）
不适用
A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C, at the doses of 2, 8 and 20 mg/d for 4 weeks, using donepezil as calibrator, in patients with mild Alzheimer's Disease.Alzheimer's DiseaseEUCTR2007-001639-80-SEsanofi-aventis recherche & développement200